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Background
Ameloblastoma is the most frequently encountered neo-
plasm arising from the odontogenic epithelium. Beclin-1
protein plays a critical role in autophagy as a tumor sup-
pressor gene. Whereas, the Murine Double Minute 2
(MDM-2) is a cellular proto-oncogene capable, if amplified,
of causing tumor-genesis. The expression & prognostic sig-
nificance of both genes are largely unexplored, yet, in this
neoplasia. Therefore, the present investigation aimed to
assess their possible biological role in ameloblastomas.
Methods
This study was done among 35 studied cases: 29 cases
of benign ameloblastomas, and 6 cases of ameloblastic
carcinomas. Labeled Streptavidin Biotin (LSAB + Dako)
immunohistochemical method, utilizing monoclonal
antibodies for Beclin-1 & MDM-2 genes, was used.
Results
Most of the benign ameloblastomas, 25 out of 29 cases
(86%), showed intense total cell positivity for the Beclin-1,
while, the ameloblastic carcinomas revealed mild (3 out of
6 cases, 50%) to negative expression (3 cases: 50 %). Inver-
sely, the MDM-2 oncoprotein demonstrated intense
brown total cell reactivity in amelobastic carcinoma (5 out
of 6 cases, 83% positivity) & loss of the reaction (21 cases:
72%) to mild brown stain (8 cases:28%) in benign amelo-
blastoma. These findings were statistically significant.
Conclusion
Based from these findings, one could conclude that,
MDM-2 could be a specific marker to identify the
proliferative activity, tumor aggressiveness & directly
proportional with the degree of malignancy. In contrast,
the high Beclin-1 expression could be a good indicator
of prognosis in ameloblastomas. Hence, an overall com-
parison, both studied genes may be very promising
molecular prognostic biomarkers.
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